Four New Biotechs to Watch: Esker, Mogrify, Isolere and BridGene

There’s money on the move and venture capital firms launch several biotech companies with hefty Series A financing rounds. Here’s a look.

Esker Launches with $70 Million Series A

San Francisco-based Esker Therapeutics, a Foresite Labs-incubated company, launched with a $70 million Series A financing. The round was led by Foresite Capital. The company focuses on autoimmune diseases and so-called precision therapies that target patients most likely to benefit from them.